Relmada Therapeutics (RLMD) Income towards Parent Company (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Income towards Parent Company data on file, last reported at -$18.5 million in Q1 2026.

• Income towards Parent Company for Q1 2026 came in at -$18.5 million, down 4.07% year-over-year; the trailing twelve-month figure through Mar 2026 was -$58.4 million (up 23.33% YoY), and the FY2025 annual result was -$57.7 million, up 28.19% from the prior year.
• Income towards Parent Company improved to -$18.5 million in Q1 2026 per RLMD's latest filing, from -$19.9 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at -$9.9 million in Q2 2025 and troughed at -$45.5 million in Q2 2022.
• A 5-year average of -$24.5 million and a median of -$21.9 million in 2024 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2022 and 2025: Income towards Parent Company sank 71.99% in 2022, then surged 54.5% in 2025.
• A 5-year view of Income towards Parent Company shows it stood at -$38.7 million in 2022, then soared by 33.93% to -$25.6 million in 2023, then gained by 27.96% to -$18.4 million in 2024, then slipped by 8.28% to -$19.9 million in 2025, then advanced by 7.24% to -$18.5 million in 2026.
• Business Quant data shows RLMD's Income towards Parent Company at -$18.5 million in Q1 2026, -$19.9 million in Q4 2025, and -$10.1 million in Q3 2025.